Bone Biologics (OTC:BBLG) Shares Up 2.3% – Time to Buy?

Shares of Bone Biologics Co. (OTC:BBLG) shot up 2.3% on Thursday . The stock traded as high as $1.7713 and last traded at $1.76. 34,818 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 45,740 shares. The stock had previously closed at $1.72.

Bone Biologics Trading Down 1.7%

The stock has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $2.15. The firm has a market capitalization of $3.11 million, a P/E ratio of -0.48 and a beta of 0.74.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.